Answers are grounded in this paper and cite their sources.
CMX001 (hexadecyloxypropyl-cidofovir, Brincidofovir) is a broad spectrum, lipid conjugate of cidofovir that is converted intracellularly into the active antiviral, cidofovir diphosphate. The lipid conjugation results in oral bioavailability, higher intracellular concentrations of active drug, lower plasma concentrations of cidofovir and increased antiviral potency against dsDNA viruses.
No takes yet. Share an insight, caveat, or question.
Florescu et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: